Financial News Feed

Stronger Sell Today ADAP ranks #5310 as SELL CANDIDATE #5310 Weaker Sell

Adaptimmune Therapeutics plc stock forecast

ADAP stock forecast

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY )( reacted to the news of the initiation of cellulite trial) Eidos Therapeutics Inc (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 29) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) Allergan plc (NYSE: AGN ) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) Aptinyx Inc (NASDAQ: APTX ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) CAN-FITE BIOPHA/S ADR (NYSE: CANF )(reacted to its first-quarter results and an update on clinical trial progress) Cidara Therapeutics Inc (NASDAQ: CDTX ) Diplomat Pharmacy Inc (NYSE: DPLO ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Emergent Biosolutions Inc (NYSE: EBS ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Hookipa Pharma Inc (NASDAQ: HOOK ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Opko Health Inc. (NASDAQ: OPK ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA )( downgraded by UBS to Neutral on its legal woes) Theravance Biopharma Inc (NASDAQ: TBPH ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Unity …...

Read more

No summary available....

Read more

Adaptimmune beats by $0.27
11:36am, Monday, 06'th May 2019
No summary available....

Read more

- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal cells - - Lentiviral transduction of hiPSC-derived cells with a SPEAR TCR produces transduced T-cells that can respond to cancer targets in vitro - PHILADELPHIA and OXFORDSHIRE, U.K., May 02, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ: ADAP ), a leader in T-cell therapy to treat cancer, will present new and compelling data during an oral presentation about its off-the-shelf SPEAR T-cell program at the annual American Society of Gene & Cell Therapy (ASGCT) meeting. Data indicate that T-cells can be generated from Human Induced Pluripotent Stem Cells (hiPSC) in vitro and that these T-cells respond to cancer targets via engineered SPEAR TCRs. This process will be used to investigate the ability of this off-the-shelf SPEAR T-cell product to fight cancer. "Our three autologous SPEAR T-cell therapies are already in the clinic and have the potential to treat cancer in multiple solid tumor indications," said Rafael Amado, Adaptimmune's President of R&D. "Beyond the promise of our current autologous therapies, this allogeneic approach – or more simply ‘off-the-shelf' product – could offer treatment to more patients more quickly, and provide a …...

Read more

Investors may be interested in following the opinion signal on shares of Adaptimmune Ther Ads (ADAP). For the current trading period, we can see that the opinion signal on the stock is 8% Sell. Headin...

Read more

Following shares of Adaptimmune Ther Ads (ADAP), we have noted that the Percentage Price Oscillator is currently higher than the signal line. Traders watching this indicator will be looking for signs ...

Read more

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) making news as their share price hit $4.08 at the end of the most recent trading day. Considering that price volatility is equivalent to risk, a commodity’...

Read more

Investors may be studying some short-term indicators on shares of Adaptimmune Ther Ads (ADAP). The current 7-day average directional indicator is Buy. This signal may be used to determine the market t...

Read more

Adaptimmune Ther Ads (ADAP)’s moving averages reveal that the Tenkan line of the shares are below the Kijun-Sen line, indicating potential downward momentum building in the bearish chart. Adaptimmun...

Read more

Adaptimmune Ther Ads (ADAP) shares are on chartist’s watch as the stock is edging above the MACD Histogram zero line. Current levels place the share price around 4.30, while the MACD indicates a bul...

Read more

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has been in the news after the price of the stock hit $4.08 at the conclusion of the most recent close. The stock is traded on NSDQ in the Medical sector and...

Read more

Taking a look at Adaptimmune Ther Ads (ADAP) stock, we have recently spotted the Percentage Price Oscillator Histogram line above zero. Traders may be taking note of this level as a possible buy signa...

Read more

Tracking shares of Adaptimmune Ther Ads (ADAP), we have spotted Span A below Span B. Traders following this signal will be looking for possible signs of a bearish shift. Successful investors are typic...

Read more

Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Tuesday. A number of other analysts have also recently ...

Read more

Tracking shares of Cloudcall Group Plc (CALL.L), we have seen that the stock price has fallen -21.08% over the last month. Focusing on the past week, shares have moved -19.53%. Zooming out to the last...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank